Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Chemotherapy

Current drugs still have potential in advanced ovarian cancer

Nature Reviews Clinical Oncology volume 7, pages 191–193 (2010)Cite this article

Subjects

Dose-dense administration of paclitaxel as well as intraperitoneal administration of platinum and paclitaxel as first-line treatments provide similar advantages compared with standard treatment in advanced ovarian cancer. Both approaches, however, need to be confirmed by additional studies. A low dose of pegylated liposomal doxorubicin combined with carboplatin is superior to standard paclitaxel and carboplatin in relapsed platinum-sensitive ovarian cancer.

In the confusion surrounding interesting new drugs, all with difficult-to-remember names, mostly ending with '-mab' or '-nib', it is easy to ignore less dramatic developments in classic anti-cancer drugs. Three recent studies have shown significant improvements in patients with advanced ovarian cancer through the use of advances in drug delivery and drug formulation of chemotherapeutic agents.1,2,3

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

Figure 1: Comparison of a | PFS and b | overall survival curves from the JGOG study on dose-dense therapy and the GOG study on IP therapy.1,2

References

  1. Katsumata, N. et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 374, 1331–1338 (2009).

    CAS  Article  PubMed  Google Scholar 

  2. Armstrong, D. K. et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354, 34–43 (2006).

    CAS  Article  PubMed  Google Scholar 

  3. Pujade-Lauraine, E., Mahner, S., Kaern, J., Gebski, M., Heywood, P. et al. A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG). J. Clin. Oncol. 27, 18s LBA5509. (2009).

    Article  Google Scholar 

  4. McGuire, W. P. et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334, 1–6 (1996).

    CAS  Article  PubMed  Google Scholar 

  5. Piccart, M. J. et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin- cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J. Natl Cancer Inst. 92, 699–708 (2000).

    CAS  Article  PubMed  Google Scholar 

  6. du Bois, A. et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference. Ann. Oncol. 16, viii7–viii12 (2005).

    Article  PubMed  Google Scholar 

  7. Bookman, M. A. et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J. Clin. Oncol. 27, 1419–1425 (2009).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  8. du Bois, A. et al. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. J. Clin. Oncol. 24, 1127–1135 (2006).

    CAS  Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Cancer Epidemiology and South Swedish Regional Tumour Registry, Lund University and Lund University Hospital, SE-221 85, Lund, Sweden

    Thomas Hogberg

Authors
  1. Thomas Hogberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Hogberg, T. Current drugs still have potential in advanced ovarian cancer. Nat Rev Clin Oncol 7, 191–193 (2010). https://doi.org/10.1038/nrclinonc.2010.37

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2010.37

Further reading

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing